Abstract: The present invention relates to dioxocyclopentyl hydroxamide derivatives of the formula wherein X, Z and Q are as defined in the specification, and to pharmaceutical compositions and methods of treatment thereof.

Abstract: Monofluoromethyl ethylene carbonate, difluoromethyl ethylene carbonate and trifluoromethyl ethylene carbonate are provided as novel compounds. These compounds are very useful as solvents because they are chemically and physically stable, have a high dielectric constant, can readily dissolve organic substances and have a wide application temperature range. These compounds have excellent charge and discharge cycle characteristics, have a high flash point, and are safe as non-aqueous elecytrolytes. Hence, batteries using these compounds withstand voltage and have excellent charge and discharge cycle characteristics.

Abstract: There is disclosed a novel amino glycol derivatives of L-N.sup.6 -(1-iminoethyl)lysine, pharmaceutical compositions containing these novel compounds, and to their use in therapy, in particular their use as nitric oxide synthase inhibitors.

Abstract: Reacting a diol (1) with a carbonic ester (2) to produce a cyclic carbonic ester (3) using a salt of a weak acid with an alkaline metal or alkaline earth metal as a catalyst. The diol (1) contains diols having an asymmetric carbon atom. The reaction mixture is neutralized and distilled to obtain a cyclic carbonic ester. Cyclic carbonic esters are produced using an easily accessible and easy to handle reactant, with good yield and under mild and moderate conditions.

Abstract: The invention concerns a method for preparing glycerol carbonate. This method consists of making urea and glycerol react at a temperature substantially between 90.degree. C. and 220.degree. C. in the presence of a catalyst bearing Lewis acid sites, in particular metallic or organometallic salts or supported metallic compounds. The invention enables glycerol carbonate to be obtained, by a catalytic carbamoylation/carbonation reaction, in a highly pure state under economic conditions.

Abstract: The synthesis of taxol and other tricyclic and tetracyclic taxanes.

Abstract: Monomers with cyclic carbonate groups of the formula I are suitable for the production of photosensitive recording materials, for example for the production of offset printing plates ##STR1## in which A means an (n+m)-valent hydrocarbon residue with 3 to 30 C atoms, which may be OH-substituted and may contain up to 8 ether bridges,R means H or methyl;n means an integer from 1 to 5;m means an integer from 1 to 3, providing that n+m is at least 3.

Abstract: A process for decolorizing organic carbonates, for example, cyclic alkylene carbonates, which involves contacting a discolored organic carbonate with hydrogen peroxide, is disclosed.

Abstract: The present invention relates to novel 10-deacetyl-14.beta.-hydroxybaccatine III derivatives. The novel derivatives, having cytotoxic and antitumour activity, are prepared from this synton after functionalization of the hydroxyls at 1-, 14- as thiocarbonate, iminocarbonate and sulfite and possible oxidation of the hydroxyl at C.sub.10. These derivatives are subjected to a subsequent esterification at position 13- with a variously substituted isoserine chain. The products of the invention can be administered by the injective or oral route, when suitably formulated.

Abstract: A compound of formula (IV) ##STR1## wherein R.sup.1 is hydrogen, an alkyl, alkoxy, alkylamino, alkylthio, aryl, aryloxy, or halogen residue; R is an alkyl, or aryl residue, and X is S or C, which is a valuable intermediate for producing Diltiazem.

Abstract: The invention describes useful conjugates of sulforhodamine, wherein the conjugated substance and the fluorophore are separated by an alkanoic acid spacer that is attached to the fluorophore via a sulfonamide bond. The increased length of the covalent linkage due to the spacer results in dye-conjugates having a number of surprisingly advantageous properties relative to previous sulforhodamine-labeled conjugates, including increased fluorescence.

Abstract: A process for the manufacture of 4,4-disubstituted 5-methylene-1,3-dioxolan-2-ones ("cyclocarbonates") of the formula: ##STR1## wherein R.sup.1 and R.sup.2 each independently signify a saturated or olefinically-unsaturated aliphatic group or an aromatic group, or R.sup.1 and R.sup.2 together form tetra- or pentamethylene, by reacting a corresponding 3,3-disubstituted prop-1-yn-3-ol of the formula HC.tbd.C--C(R.sup.1)(R.sup.2)--OH (II) with carbon dioxide in the presence of a quaternary ammonium or phosphonium salt as the catalyst comprises using a silver salt as a further catalyst. An alkali metal or quaternary ammonium or phosphonium salt of a carboxylic acid can also be used to increase the catalytic performance of the silver salt catalyst. Moreover, the addition of triphenylphosphine serves to accelerate the reaction to some extent. The silver salts catalyze this process significantly better than the previously utilized copper salts.

Abstract: Novel compounds of the formula: ##STR1## are disicosed which are endothelin receptor antagonists.

Abstract: Polymerizable aromatic carboxylic acids and carboxylic acid anhydrides with cyclic carbonate groups which are useful for improving adhesion of synthetic dental filling materials.

Abstract: A method for esterifying C13 deoxy taxoid intermediates employs three steps, i.e., oxygenation of the C13 deoxy taxoid intermediate to produce a C13 enone taxoid intermediate; reduction of the C13 enone to produce an alcohol; followed by esterification of the C13 alcohol. Key intermediates include C13 deoxy taxoids; C13 enone substituted taxoids; and C1-C2 cyclo carbonate esters of taxoids.

Abstract: A compound of the formula (I) or its pharmaceutically acceptable salt or ester: ##STR1## wherein each of ##STR2## which are the same or different, is an aryl group or a heteroaromatic ring group; A is a C.sub.3-8 linear saturated or unsaturated aliphatic hydrocarbon group which may have substituent(s) selected from the group consisting of a lower alkyl group, a hydroxyl group, a lower alkoxy group, a carboxyl group, an aryl group and an aralkyl group; Q is a single bond or a group of the formula --CO--O--, --O--CO--, --CH.sub.2 CH.sub.2 --, --CH.dbd.CH--, --OCH.sub.2 --, --SCH.sub.2 --, --CH.sub.2 O-- or --CH.sub.2 S--; each of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 which are the same or different, is a hydrogen atom, a halogen atom, a lower alkyl group, a hydroxyl group, a lower alkoxy group, or an aryl or heteroaromatic ring group which may have substituent(s) selected from the group consisting of a halogen atom, a lower alkyl group and a lower alkoxy group; each of R.sup.5, R.sup.6 and R.sup.

Abstract: The invention relates to urethane acrylates and urethane methacrylates containing cyclic carbonate groups, and use thereof in dental materials and lithographic plates.

Abstract: The hydrolyzable and polymerizable silanes have the formula I, ##STR1## wherein X is hydrogen, a halogen, a hydroxy, an alkoxy group, an acyloxy group, an alkylcarbonyl group, an alkoxycarbonyl group or --NR.sup.2.sub.2 group; wherein R.sup.

Abstract: Fluorine-containing dioxolane compounds and electrolytic solution compositions containing the fluorine-containing dioxolane compounds are disclosed. Lithium secondary batteries or electric double layer capacitors, having various improved characteristics such as improved charge and discharge cycle life or improved durability over a long period of time can be obtained by using the electrolytic solution compositions.

Abstract: An amino acid compound of the formula: R.sup.1 NH--CH(R.sup.2)--COHN--A--ONO.sub.2, wherein R.sup.1 represents a hydrogen atom, a C.sub.1 -C.sub.7 alkanoyl group, a C.sub.1 -C.sub.6 alkoxycarbonyl group, a C.sub.6 -C.sub.10 arylcarbonyl group, a C.sub.7 -C.sub.13 aralkylcarbonyl group, a C.sub.7 -C.sub.13 aralkyloxycarbonyl group or a 5- or 6-membered aromatic heterocyclic carbonyl group; R.sup.2 represents a substituted C.sub.1 -C.sub.6 alkyl group; and A represents a C.sub.2 -C.sub.5 alkylene group; and pharmacologically acceptable salts thereof. The amino acid compound has an excellent vasodilator action for collateral vessels and is useful for treating angina pectoris.

Abstract: Isolation of a new taxane having pharmaceutical activity, 1a 14-beta-hydroxy-10-deacetyl-baccatine III and hemisynthesis of some derivatives useful as antitumor agents and intermediates.

Abstract: An improved method for the preparation of acyclic nucleotide analogues comprises first condensing a cyclic carbonate with a purine or pyrimidine base and then reacting the alkylated base with an activated phosphonate. Novel cyclic carbonates are employed to yield the desired phosphonylmethoxyalkyl nucleotide analogues.

Abstract: The present invention provides a method for chemically modifying non-ionic, water soluble particulate contrast agents so that they degrade in vivo to their non-ionic parent contrast material and carbon dioxide. According to the present invention, known particulate, non-ionic contrast agents are chemically modified to form a precursor or "prodrug" comprising cyclic carbonates and carbamates of the parent compound. The resulting cyclic carbonates and carbamates are lipid soluble, biodegradable, and can be prepared in large quantities using well-established methods. These cyclic carbonates and carbamates can be converted to particulate contrast media using simple, well known techniques, such as solvent-extraction or solvent evaporation.

Abstract: Carboxy-peptidyl compounds of Formula I are found to be useful inhibitors of matrix metalloendoproteinase-mediated diseases including osteoarthritis, rheumatoid arthritis, septic arthritis, tumor invasion in certain cancers, periodontal disease, corneal ulceration, proteinuria, dystrophobic epidermolysis bullosa, coronary thrombosis associated with atherosclerotic plaque rupture, and aneurysmal aortic disease. This invention relates to a process of making the carboxy-peptidyl compounds of formula I.

Abstract: The synthesis of taxol and other tricyclic and tetracyclic taxanes.

Abstract: The invention relates to diacrylates and dimethacrylates having cyclic carbonate groups, and their use in dental materials.

Abstract: A process is provided for preparing dioxolenone derivatives of the structure ##STR1## wherein R is alkyl or aryl and R.sub.3 is CO.sub.2 R.sub.2 (where R.sub.2 is alkyl or arylalkyl such as benzyl, diphenylmethyl or para-methoxybenzyl). Intermediates produced in the above process are also provided as well as a method for preparing squalene synthetase inhibitors employing such intermediates.

Abstract: A compound of the formula (I) or its pharmaceutically acceptable salt or ester: ##STR1## and intermediates thereof.

Abstract: The present invention provides three basic routes for the total synthesis of taxol having the structure: ##STR1## The present invention also provides the intermediates produced in the above processes, processes for synthesizing these intermediates as well as analogues of taxol and nortaxol.

Abstract: Process for the preparation of a derivative or analog of baccatin III or 10-desacetyl baccatin III having a C2 substituent other than benzoate and/or a C4 substituent other than acetate in which the C2 benzoate substituent and/or the C4 acetate substituent of a derivative of baccatin III or 10-desacetyl baccatin III is/are selectively reduced to the corresponding hydroxy group(s) and converted to R.sub.7 COO-- and/or R.sub.8 COO--, respectively, wherein R.sub.7 and R.sub.8 are independently H, C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.2 alkenyl, C.sub.2 -C.sub.6 alkynyl, moncyclic aryl, or monocyclic heteroaryl.

Abstract: The inventive Oxalylamino-benzofuran- and benzothienyl-derivatives are prepared by reacting the appropriate amino substituted benzofuranes and benzothiophenes with oxalic acid derivatives. The inventive compounds are suitable for the prevention and treatment of acute and chronic inflammatory processes, particularly of the airways.

Abstract: Water-insoluble iodinated esters of the formula (I) ##STR1## useful in X-ray and ultrasound imaging, are disclosed.

Abstract: Amidinonaphthyl furancarboxylate derivatives of the formula I ##STR1## wherein A is a single bond or A denotes (a) a phenyl group, cyclopentyl group, or cyclohexyl group,(b) an alkenylphenyl group, alkylphenyl group, phenylalkenyl group, or phenylalkyl group wherein alkyl is C.sub.1 to C.sub.7 alkyl and alkenyl is C.sub.2 to C.sub.7 alkenyl,(c) a C.sub.1 to C.sub.18 alkyl or C.sub.2 to C.sub.7 alkenyl group which may be substituted by one or two substituents selected from C.sub.1 to C.sub.5 alkyl groups and quanidino groups, wherein an alkyl substituent together with the carbon atom to which it is attached may form a cycloalkyl ring having from 3 to 6 carbon atoms, or said C.sub.1 to C.sub.5 alkyl may itself be substituted by a C.sub.3 to C.sub.6 cycloalkyl ring, or(d) --(CH.sub.2).sub.n --NH--CO--(CH.sub.2).sub.n' wherein n and n' may be the same or different and represent an integer from 1 to 4; andwherein R denotes(e) a hydroxyl group,(f) a C.sub.1 to C.sub.

Abstract: The present invention relates to 7-[carboxyalkyl or alkenyl]-6-[alkyl or alkenyl]-3-oxo-2,4-dioxobicyclo[3.2.1]octanes and derivatives thereof. In particular, hydroxyl, nitro, amino, amido, azido, oxime, thiol, ether and thiol ether derivatives of said carboxy group are contemplated. In particular, 7-[6-carboxy-2-hexenyl]-6-[3-hydroxy-1-octenyl] of 3-oxo-2,4-dioxobicyclo-[3.2.1 ]octane and derivatives thereof are disclosed. These compounds are useful as ocular hypotensives and as (a) thromboxane mimetics for the prevention of hemorrhaging as follows:, during surgery; tooth extraction; hemorrhaging associated with gastro-intestinal diseases and conditions such as hemorrhoids, inflammatory bowel diseases and gastric and peptic ulcers; as a result of stroke; as a complication in retinal diseases resulting in impaired vision and associated with-menstruation, childbirth and uterine dysfunction and (b) selective vasoconstrictors for treating systemic hypotension, e.g.

Abstract: An improved method for the preparation of acyclic nucleotide analogues comprises first condensing a cyclic carbonate with a purine or pyrimidine base and then reacting the alkylated base with an activated phosphonate. Novel cyclic carbonates are employed to yield the desired phosphonylmethoxyalkyl nucleotide analogues.

Abstract: Ethylene glycol carbonate (EGC) can be isolated in purified form from contaminated material which contains impurities from the group comprising starting materials, by-products and/or catalysts of the preparation process in that the contaminated EGC is subjected to a fractional melt crystallization and the crystals of the purified EGC formed in this case are mechanically separated off from the remaining impurities dissolved in the residual melt.

Abstract: A bubble column reactor is described which is characterized by a slenderness ratio at a ratio of height to diameter of 2 to 50, a feed, at the bottom end of the bubble column, for the ethylene glycol carbonate (EGG) or propylene glycol carbonate (PGC) already present serving as reaction medium, one or more metering sites for the starting materials CO.sub.2 and ethylene oxide (EOX) or propylene oxide (POX) above the feed for the reaction medium, an outlet for the reaction mixture at the top end of the bubble column, a dividing apparatus connected thereto for the reaction mixture flowing off for dividing it into reaction mixture to be taken off and worked up on the one hand and reaction mixture to be recycled on the other hand and additionally a return line to the feed for the reaction mixture to be recycled. This bubble column reactor can be advantageously used in a process for the continuous preparation of EGG or PGC which is carried out in the temperature range from 100.degree. to 200.degree. C.

Abstract: The present invention provides three basic routes for the total synthesis of taxol having the structure: ##STR1## The present invention also provides the intermediates produced in the above processes, processes for synthesizing these intermediates as well as analogues of taxol and nortaxol.

Abstract: Bioactive ABC taxoids accessible by convergent synthesis have an intact AB ring framework of taxol, including the C.sup.13 side chain, and an aromatic C ring which substitutes for the CD ring system found on native taxol. The aromatic C ring may be substituted or unsubstituted. MPT derivatives of ABC taxoids are also disclosed.

Abstract: This invention relates to a the use of new oxodioxolenylmethyl carbamates to produce bioreversible neutral prodrugs from primary and secondary amines.

Abstract: A process is described for the catalytic preparation of propylene glycol carbonate (PGC) by reacting propylene oxide (POX) and CO.sub.2 in PGC as reaction medium at elevated temperature and elevated pressure and separating off from the catalyst the PGC formed. The process is carried out continuously under adiabatic temperature conditions. Per unit of time, PGC as reaction medium flows into the reactor at 7 to 350 times the amount of the PGC formed per unit of time. At all points of the reactor a CO.sub.2 excess is maintained over the other reaction partner POX. Of the effluent reaction mixture, 80 to 98% by weight are returned to the entrance of the reactor, while the remainder is worked up to give PGC. The sensible heat of the reaction product resulting from the adiabatic temperature conditions can be used for the work-up.

Abstract: A method for the production of an alkylene carbonate at high yields and high selectivity by a reaction between an alkylene glycol and urea, the method being capable to preventing the deposition of a white crystal in the reflux condenser used in a conventional method for the production of alkylene carbonate and the subsequent decrease in the yield, wherein:a gas washing member and a cooling member are disposed above a reaction portion where alkylene glycol and urea are allowed to react,ammonia-containing steam exhausted from the reaction portion is downwardly introduced into the cooling member through the gas washing member,condensate and ammonia gas exhausted from a bottom of the cooling member are gas-liquid separated,the condensate is introduced into the gas washing member, andthe ammonia gas is removed from the reaction system.

Abstract: The present invention relates to 7-[carboxyalkyl or alkenyl]-6-[alkyl or alkenyl]-3-oxo-2,4-dioxobicyclo[3.2.1 ] octanes and derivatives thereof. In particular, hydroxyl, nitro, amino, amido, azido, oxime, thiol, ether and thiol ether derivatives of said carboxy group are contemplated. In particular, 7-[6-carboxy-2-hexenyl]-6-[3-hydroxy-1-octenyl] of 3-oxo-2,4-dioxobicyclo-[3.2.1] octane and derivatives thereof are disclosed. These compounds are useful as ocular hypotensives and as (a) thromboxane mimetics for the prevention of hemorrhaging as follows:, during surgery; tooth extraction; hemorrhaging associated with gastro-intestinal diseases and conditions such as hemorrhoids, inflammatory bowel diseases and gastric and peptic ulcers; as a result of stroke; as a complication in retinal diseases resulting in impaired vision and associated with menstruation, childbirth and uterine dysfunction and (b) selective vasoconstrictors for treating systemic hypotension, e.g.

Abstract: Water insoluble iodinated esters of formula (I), in which R.sup.1 is a substituted or unsubstituted C.sub.1-20 aliphatic, C.sub.7-20 araliphatic or C.sub.6-20 aryl group or a C.sub.1-20 heterocyclic group having one or more hereto atoms selected from O, S and N; R.sup.2 is hydrogen or a substituted or unsubstituted C.sub.1-6 aliphatic, C.sub.6-10 aryl or C.sub.7-20 araliphatic group; and R.sup.3 is a group as defined above for R.sup.1, which may be the same as or different from R.sup.1, or R.sup.2 and R.sup.3 together represent a substituted or unsubstituted C.sub.1-4 alkylene group, the molecule containing at least one iodine atom and being metabolisable to products which are soluble in body fluids and are physiologically acceptable. The esters are useful in X-ray and ultrasound imaging, especially liver and spleen imaging.

Abstract: Process for the synthesis of taxol and other tricyclic and tetracyclic taxanes.

Abstract: Organic carbonates and cyclic organic carbonates are prepared by reacting an aliphatic or cycloaliphatic alcohol, or, respectively, an aliphatic diol, with carbon monoxide and oxygen, by operating in the presence of a complex catalyst of cobalt with organic ligands bearing one or more oxygen functional groups, as electron donors.

Abstract: Alkylene carbonates can be prepared by catalytic reaction of alkylene oxides with carbon dioxide, catalysts which can be regenerated of the formulaa[MX]/b[ZnY.sub.2 ] (III)whereinM denotes an alkali metal,X and Y independently of one another denote chlorine, bromine or iodine anda and b denote fractions or integers in a range from 0.001 to 2being employed.The catalysts (III) can be regenerated by treating with a halogen compound. The halogen compounds which can be used for this purpose belong to the group comprising hydrogen halides, inorganic and organic acid halides, interhalogen compounds and organic halides with mobile halogen.

Abstract: Water insoluble iodinated esters of formula (I), in which R.sup.1 is a substituted or unsubstituted C.sub.1-20 aliphatic, C.sub.7-20 araliphatic or C.sub.6-20 aryl group or a C.sub.1-20 heterocyclic group having one or more hetero atoms selected from O, S and N; R.sup.2 is hydrogen or a substituted or unsubstituted C.sub.1-6 aliphatic, C.sub.6-10 aryl or C.sub.7-20 araliphatic group; and R.sup.3 is a group as defined above for R.sup.1, which may be the same as or different from R.sup.1, or R.sup.2 and R.sup.3 together represent a substituted or unsubstituted C.sub.1-4 alkylene group, the molecule containing at least one iodine atom and being metabolisable to products which are soluble in body fluids and are physiologically acceptable. The esters are useful in X-ray and ultrasound imaging, especially liver and spleen imaging.

Abstract: This invention relates to compounds of structural formula (I): ##STR1## which are squalene synthase inhibitors and thus useful as cholesterol lowering agents and antifungal agents. These compounds are also inhibitors of farnesyl protein transferase and farnesylation of the oncogene protein Ras and thus useful in treating cancer.

Abstract: New cholesterol lowering compounds are formed from the photochemical treatment of zaragozic acid A.